Anavex Life Sciences Corp (OTCMKTS:AVXL) a known clinical-stage biopharmaceutical firm working on drug candidates to treat CNS diseases and Alzheimer presented promising preclinical data for its ANAVEX 3-71 and ANAVEX 2-73 drug candidates. The data was disclosed in two separate presentations at the world-famous 2015 International Conference on ‘Alzheimer’s and Parkinson’s Diseases’ in France.
The details
Tangui Maurice, PhD who is a part of the Scientific Advisory Board of Anavex Life established for the first time the crucial role of S1R via ‘S1R Knock out’ on memory and survival in the existence of amyloid. At present, drug candidate ANAVEX 2-73 is in Phase 2a study in patients suffering from Alzheimer. The Phase 1 trial is concluded with a clean data profile. In last preclinical trials, drug candidate ANAVEX 2-73 showed potential to reverse or halt Alzheimer’s disease. Also, positive preclinical findings highlight the potential for ANAVEX 2-73 as a main drug to cure other CNS disorders.
The presentation
Anavex’s second presentation was on ANAVEX 3-71 which was earlier called as AF710B. It is a promising and novel preclinical drug with a pioneering mechanism of action said to enhance cognition and neuroprotection in fatal disease Alzheimer. It can be better called as CNS-penetrable mono treatment that bridges treatment of cognitive impairments and disease modifications. There are numerous benefits including lessening of inflammation and mitochondrial dysfunctions.
Promising data
Christopher U. Missling, PhD, the CEO of Anavex stated that with the presented data the company is optimistic to have the two drugs currently in the trial process and will update on the progress of the study in next quarter. The company’s lead drug candidate ANAVEX 3-71 demonstrated encouraging broad therapeutic advantages in Alzheimer’s disease provided its capacity to boost neuroprotection and cognition via SIR activation.
On Wednesday’s trading session, Anavex stock price jumped 9% to close at $0.230 at volume of 1.76 million.
